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Sixty-five patients with symptomatic, drug-refractory, sus- 
tained ventricular tachycardia or fibrillation were treated 
with oral sotalol (80 to 480 mg twice daily). Sotalol was 
withdrawn in 11 patients because of continued inducibility 
of ventricular tachycardia at the time of follow-up elec- 
trophysiologic study. Therefore, the clinical effectiveness of 
sotalol could be evaluated in 54 patients followed up for 
11.5 f 6 months (range 0.2 to 25). The actuarial incidence 
of successful sotalol therapy was 54 f 13% at 6 months and 
47 f 13% at 12 months. In 39 patients who underwent 
electrophysiologic testing while receiving oral sotalol, the 
drug prevented the reinduction of ventricular tachycardiai 
fibrillation in 8 (20%). During follow-up study, arrhythmia 
recurred in 1 (17%) of 6 patients whose ventricular tachy- 
cardia was noninducible with oral sotalol and in 8 (44%) of 
18 with inducible tachycardia but who were continued on 
oral sotalol therapy. 
Adverse effects were noted in 28 patients (42%), requir- 
ing drug withdrawal in 13 (22%) and dose reduction after 
hospital discharge in 10 (15%). Exacerbation of ventricular 
arrhythmia occurred in six patients (9%), one of whom had 
associated hypokalemia. 
Sotalol is frequently useful in the control of intractable, 
life-threatening ventricular arrhythmias, and its efficacy 
appears to be predicted by programmed stimulation. How- 
ever, there is a high rate of limiting side effects, which 
precludes its use in a large number of patients, and a 
substantial risk of arrhythmia exacerbation. 
Cl Am Co11 Cardiol 1989;13:145-52) 
Sotalol is a nonselective beta-adrenergic blocker that also 
increases the cardiac action potential duration both in vitro 
(1,2) and in vivo (31, consistent with class III antiarrhythmic 
activity. It has been used to treat atrial (4). junctional (5). 
atrioventricular (AV) reciprocating (6,7) and ventricular 
tachyarrhythmias (8-13). Early reports (8-11) suggest that 
sotalol prevents the induction of ventricular tachycardia in 
44 to 67% of patients with a similar rate of clinical success 
and that it has a low incidence of serious adverse effects. 
We report our experience using sotalol in 65 patients with 
drug-refractory sustained ventricular tachycardia or ventric- 
ular fibrillation, including observations on its efficacy for 
preventing the induction of ventricular tachycardia/fibrilla- 
tion, its long-term clinical effectiveness and adverse effects 
as well as its use in patients with an implanted defibrillator. 
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Methods 
Study patients. All patients in this study had symptom- 
atic, drug-refractory, sustained ventricular tachycardia or 
fibrillation. The patients provided written informed consent, 
and the study was approved by the Institutional Review 
Board at Sequoia Hospital. Sixty (92%) of the 65 patients 
underwent baseline right and left heart catheterization with 
coronary and left ventricular angiogrdphy to evaluate under- 
lying cardiac disease and assess left ventricular function. In 
the remaining five patients, left ventricular function was 
assessed by echocardiography (three patients) or radionu- 
elide angiography (two patients). Patients with an ejection 
fraction ~0.20 and those who had a contraindication to 
beta-adrenergic blockade or evidence of decompensated 
congestive heart failure were excluded from sotalol therapy. 
The patients treuted with sotalol bvue categorized into 
three grorrps. Group I (45 patients) were those undergoing 
serial electrophysiologic study. These patients had been 
unsuccessfully treated with other drugs at electrophysiologic 
study, and underwent sotalol therapy to suppress inducible 
ventricular tachycardiaifibrillation. Grorrp I1 (IO patients) 
included those who had recurrent ventricular tachycardiai 
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fibrillation. and after unsuccessful trials with other anti- 
arrhythmic drugs or antiarrhythmic surgery, or both, had an 
automatic defibrillator implanted at some time (range 3 to 42 
months) before starting sotalol therapy. These 10 patients 
then became intolerant to drugs (primarily amiodarone) 
given concomitantly with the defibrillator or experienced 
numerous defibrillation discharges. Group III (10 patients) 
were those who had recurrent ventricular tachycardia/fibril- 
lation and had been unsuccessfully treated with other agents 
(as evidenced by either clinical recurrence or inducible 
ventricular tachycardialfibrillation) before sotalol adminis- 
tration. Follow-up electrophysiologic study of patients re- 
ceiving sotalol was omitted in this group because arrhythmia 
prevalence was such that noninvasive assessment of drug 
efficacy was felt to be possible or no other reasonable 
therapy (including an implantable defibrillator) was appro- 
priate. 
Predischarge follow-up. Patients in Group 1 (those under- 
going serial electrophysiologic study) were discharged on 
sotalol therapy if 1) ventricular tachycardiaifibrillation was 
no longer inducible while they were receiving oral sotalol; 2) 
ventricular tachycardiaifibrillation was inducible while they 
were receiving sotalol, but they subsequently underwent 
defibrillator implantation and sotalol effectively suppressed 
spontaneous ventricular arrhythmias during prolonged elec- 
trocardiographic (ECG) monitoring; or 3) ventricular tachy- 
cardia/fibrillation was inducible while they were receiving 
sotalol, but the agent suppressed spontaneous ventricular 
arrhythmias during prolonged monitoring and multiple other 
antiarrhythmic drugs had proven ineffective clinically or at 
follow-up electrophysiologic study. Patients in Group II 
(with a previously implanted defibrillator) were discharged 
on sotalol therapy if the drug appeared to control spontane- 
ous arrhythmia recurrence during prolonged ECG monitor- 
ing. Patients in Group III were discharged on sotalol if it 
suppressed spontaneous ventricular arrhythmias during pro- 
longed ECG monitoring. 
Electrophysiologic studies. All patients underwent a base- 
line electrophysiologic study using up to three ventricular 
extrastimuli at three pacing cycle lengths (600, 500 and 400 
ms) and rapid ventricular pacing under a previously defined 
protocol (14). The end point was sustained ventricular tachy- 
cardia or fibrillation. Stimulation was begun at the right 
ventricular apex and continued, if necessary, at the right 
ventricular outflow tract. Tachycardia was induced two or 
more times to assess the reproducibility of induction. 
Ventricular tachycardia/fibrillation was considered to be 
“noninducible” at follow-up electrophysiologic study only if 
stimulation at two pacing sites with three extrastimuli failed 
to induce a sustained ventricular tachyarrhythmia. Changes 
in the number of extrastimuli needed for induction, the 
configuration of induced ventricular tachycardia and the site 
of stimulation needed were not considered factors in terms 
of electrophysiologically defined success. In general, the 
function of the sinus or AV node was not reassessed at the 
time of follow-up study. 
Drug administration. Throughout hospitalization, pa- 
tients remained on continuous ECG monitoring. Whenever a 
patient’s clinical status and prior drug half-life permitted, a 
24 h ambulatory ECG record was obtained at a time when 
the patient was not taking any antiarrhythmic drug. 
Sotulol was initiated orally at a dose of 80 mg twice a day 
and the dose was increased in a stepwise fashion, no more 
often than every 72 h. The end points of dose increase were 
side effects, symptomatic bradycardia or a maximal dose of 
240 mg twice daily. A dose >240 mg twice daily was used 
only for those patients who had recurrent ventricular tachy- 
cardiaifibrillation while receiving a lower dose (three 
patients). 
Clinical follow-up. Patients discharged from the hospital 
were closely followed up as outpatients with physical exam- 
ination, ECG, routine blood chemistry evaluation, urinalysis 
and 24 h ambulatory ECG recording obtained at 2 weeks, 1 
month, 3 months and every 3 months thereafter. The clinical 
effect of sotalol was assessed during follow-up study with the 
following criteria. It was judged 1) effective if no sustained 
symptomatic arrhythmia occurred after a maintenance dose 
was established; 2) partly effective if the frequency of 
spontaneous recurrence of sustained ventricular arrhythmias 
decreased significantly; or 3) ineffective if sustained ventric- 
ular tachycardiaifibrillation prevalence was unaltered or 
sudden death occurred. It was recognized that patients with 
an implanted defibrillator who received life-saving shocks 
from the device may have died in the absence of such shocks 
and that this result would not usually be considered “partly 
effective.” However, from this clinical viewpoint, sotalol 
was considered partly effective if it substantially decreased 
the number of sustained arrhythmias requiring defibrillator 
discharge or hospital admission. Simple prolongation of the 
cycle length of the clinical or induced ventricular tachycar- 
dia was not considered to be a criterion for partial success. 
Arrhythmia exacerbation. Sotalol-induced exacerbation 
of arrhythmia was diagnosed if a marked (> IO-fold) increase 
in arrhythmia prevalence or duration, or both, was seen 
corresponding to a change in sotalol dosage or initiation of 
sotalol therapy that resolved with dose reduction or drug 
withdrawal (15-17). 
Implanted defibrillators. Implantable defibrillators used 
in these patients were either Intec model AICD BR or 
Cardiac Pacemakers, Inc. Ventak 1520. These were exclu- 
sively high energy, rate-only devices. 
Statistics. Data are expressed as mean values + I SD. 
Freedom from arrhythmia recurrence was determined by 
Kaplan-Meier analysis. Student’s t test for paired data 
(two-tailed) was used to evaluate the significance of the 
changes in variables between baseline and sotalol therapy. 
For the analysis of the effect of sotalol on spontaneously 
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Table 1. Clinical Characteristics in 65 Patients 
Men 
Women 
Mean age (yr) 
Cardiac disease 
Coronary artery disease 
Idiopathic cardiomyopathy 
Valvular 
Congenital 
Arrhythmogenic RV dysplasia 
None 
Ejection fraction 
NYHA classification 
Prior CHF 
19 
16 
61 t I? 
51 
3 
1 
z 
3 
3 
0.39 f 0. I I 
1.X t 0.6 
IS 
CHF = congestive heart failure; NYHA = New York Heart Association: 
RV = right ventricular 
Begun on Sotalol 
65 
t 
11: other therapy 
because of inducibility 
3: ineffective during 
loading phase 
7: adverse effect 
Discharged on Sotalol 
+---F-3 
Effective Partly Effective ineffective 
2tL&&se ‘[2:az j 
22 11 5 
Recurrent VT 
Figure 1. Summary of the clinical effectiveness of sotalol in 6.5 
patients. VT = ventricular tachycardia. 
occurring arrhythmias, Wilcoxon scores (rank sums) were 
used. 
Results 
Patient characteristics (Tables 1 and 2). Sixty-five pa- 
tients with symptomatic, drug-refractory sustained ventric- 
ular tachycardia or fibrillation were treated with sotalol. 
Their underlying cardiac disease and cardiac function are 
shown in Table 1. Fifty-eight patients (89%) had sustained 
ventricular tachycardia, and 7 (11%) had ventricular fibrilla- 
tion (Table 2). Thirty patients (46%) had at least one spon- 
taneous episode of tachyarrhythmia causing hemodynamic 
collapse requiring either cardiopulmonary resuscitation or 
Table 2. Arrhythmia History in 65 Patients 
No. of 
Patients Q 
Arrhythmia type 
VT 
VF 
Arrhythmia severity 
No. of spontaneous episodes 
? (0 5 
6 to 9 
19 
At least one episode 
of cardiac arrest 
Mean empiric drugs failed 
Mean EP drug trials faded 
Amiodarone failures 
Recurrent VT 
Toxicit! 
Both 
58 89 
7 II 
14 
?? 
26 
30 46 
3.3 2 ?.I 
2.6 ? 1.4 
I5 23 
EP = electrophyslologic study; VF = ventricular fibrillation: VT = 
ventricular tachycardia 
immediate electric cardioversion. The patients had previ- 
ously been unsuccessfully treated with or proved intolerant 
to a mean of 3.3 t 2.1 drugs (range 1 to 10). In those 64 
patients who underwent serial drug trials, a mean of 2.6 L 
1.4 drugs proved unsuccessful at electrophysiologic testing. 
Fifteen (23%) of the patients had previously taken amioda- 
rone. Of these, nine patients were withdrawn from amioda- 
rone therapy because of toxicity, four because of recurrent 
ventricular tachycardialfibrillation and two because of both 
ventricular tachycardia/fibrillation recurrence and toxicity. 
Clinical efficacy (Fig. 1). In the 65 patients begun on 
sotalol therapy, the drug was discontinued before discharge 
because of side effects in 7 patients, continued inducibility of 
ventricular tachyarrhythmia at follow-up electrophysiologic 
study in 11 patients and frequent spontaneous arrhythmia 
recurrence in 3 patients. Forty-four patients (22 with an 
implanted defibrillator) were discharged on sotalol therapy at 
a mean dose of 364 5 127 mgiday. 
Affer discharge, side effects requiring drug withdrawal 
developed in an additional six patients. Twenty-two patients 
remain on sotalol therapy without arrhythmia recurrence at 
a mean follow-up interval of IO I 6 months (range I to 20). 
Ventricular tachycardiaifibrillation recurred in an additional 
1 I patients, but at a sufficiently reduced frequency to be 
considered partly effective. Seven of these patients had an 
implanted defibrillator and experienced presyncopal symp- 
toms before defibrillator shocks, and it is possible that the 
arrhythmia recurrence would have been fatal if the defibril- 
lator had not been present. No other therapy was considered 
more appropriate, and they continue to receive sotalol (mean 
follow-up interval of 16 + 4 months). Five patients continued 
to have recurrences of ventricular tachycardiaifibrillation 
without a noticeable change in frequency. and sotalol ther- 
apy was discontinued. Sotalol dosage in patients for whom 
the drug proved effective, partly effective and ineffective 
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drug withdrawal and in 19 a result of recurrent ventricular 
tachycardia/fibrillation. The actuarial incidence of sotalol 
efficacy was 54 2 13% at 6 months and 47 +- 13% at 12 
months. If one considers only those 41 patients receiving 
sotalol without side effects, the actuarial incidence of sotalol 
efficacy was 68 i 14% at 6 months and 56 + 15% at 12 
months. 
20 - 
0 “l~‘I’~“~J’~I”’ 
0 3 6 9 12 15 16 
Months on Drug 
Figure 2. Actuarial analysis of the efficacy of sotalol for all patients 
with ventricular tachycardiakentricular fibrillation treated with so- 
talol (solid circles) and for those patients in whom sotalol was not 
withdrawn because of side effects (open circles). The numbers 
represent the number of patients continuing on sotalol. The vertical 
bars represent the standard error. 
was 333 * 98,387 -t 143 and 384 ? 143 mglday, respectively 
(p = NS). 
TWO patients died. In one patient, sotalol was withdrawn 
3 months before death because of an adverse reaction. 
Treatment with amiodarone was begun and ultimately 
caused fatal pulmonary fibrosis. In another patient without a 
defibrillator, sudden cardiac death occurred after 9 months 
of sotalol treatment. The other 63 patients are alive. 
The actuarial incidence of sotalol eficacy was assessed 
on the basis of any spontaneous recurrence of sustained 
ventricular tachycardia or ventricular fibrillation or the oc- 
currence of side effects necessitating drug withdrawal (Fig. 
2). Although a patient’s arrhythmia prevalence may have 
been markedly reduced (considered “partly effective”), for 
this analysis a single ventricular tachycardia/fibrillation re- 
currence was considered to indicate drug failure. The 11 
patients in whom sotalol therapy was stopped because of 
continued inducibility of tachyarrhythmia were not consid- 
ered to have had unsuccessful sotalol therapy and were 
excluded from this analysis. In summary, 22 of 54 patients 
were successfully treated, and 32 failed to respond. Of these 
32, drug failures in 13 was a result of side effects requiring 
Electrophysiologic effects of oral sotalol (Table 3). In 45 
patients in whom sotalol therapy was begun during serial 
electrophysiologic study, sotalol was withdrawn in 6 be- 
cause of side effects or recurrent spontaneous ventricular 
tachycardia/fibrillation. Thirty-nine patients underwent re- 
peat electrophysiologic study while receiving oral sotalol 
(mean dose 394 ? 121 mglday). Sotalol decreased the heart 
rate by 26%; there was no significant effect on the PR and 
QRS interval. The QT and the QTc intervals increased by 23 
and 7%, respectively. The ventricular effective refractory 
period increased by 12%. Arrhythmia induction was pre- 
vented by oral sotalol in 8 patients (20%). Of these, 5 had 
ventricular tachycardia induced at baseline study and 3 had 
ventricular fibrillation. Ventricular tachyarrhythmia re- 
mained inducible in 3 1 (80%). There was no consistent effect 
of sotalol on the number of extrastimuli needed for induc- 
tion, with 24 patients exhibiting induction with the same 
number of extrastimuli, 4 with fewer extrastimuli and 3 
requiring more extrastimuli. Sotalol dose in those with 
noninducible and those with inducible ventricular tachy- 
arrhythmia at follow-up study was 340 ? 93 and 400 + 119 
mglday, respectively (p = NS). 
Twenty-nine patients had monomorphic ventricular 
tachycardia induced both at baseline and during sotalol 
therapy. The ventricular tachycardia cycle length was 290 * 
52 ms at baseline and 322 ? 52 ms during sotalol therapy (p 
< 0.05). Twenty-four of these patients also had ventricular 
tachycardia with a cycle length of 372 * 89 ms induced while 
receiving procainamide, which was significantly greater than 
the ventricular tachycardia cycle length induced during 
sotalol therapy (p < 0.02). 
The clinical long-term ejicacy of sotalol in patients with 
inducible versus noninducible ventricular tachycardialfbril- 
lation with sotalol was us follows. Of the eight patients with 
Table 3. Electrophysiologic Effects of Sotalol in 65 Patients 
Baseline Sotalol 
(ms) (ms) 
Interval (n = 65) (n = 55) % Change p Value 
RR 865 1,093 26 10.0001 
& 178 III 178 07 0 4 NS 
$c 429 394 484 59 23 7 <0.0001 co. 1 
Ventricular ERP 249 281 13 10.0001 
ERP = effective refractory period 
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Table 4. Adverse Effects in 65 Patients 
Instances 
Drug 
Stopped 
Dose 
Reduced 
Cardiac 
Bradycardia 5 
Increased CHF 9 
Hypotension 2 
Neurologic 
Depression 2 
Dizziness 2 
Gastrointestinal 
Nausea 3 
Other 
Fatigue 
Mild 2 
Severe 3 
Arrhythmia exacerbation 6 
Total 34 
CHF = congestive heart failure. 
1 
4 1 
2 
2 
I 
2 
I 
3 
2 3 
13 IO 
noninducible arrhythmia with sotalol, five are free of 
arrhythmia after 9 ? 4 months, two were withdrawn from 
sotalol because of side effects and one died suddenly after 9 
months on sotalol. Tachyarrhythmia remained inducible in 
20 patients receiving sotalol, but they were discharged on the 
drug (14 with an implanted defibrillator). Sotalol was discon- 
tinued in 2 of these 20 patients because of side effects. Eight 
(44%) of the remaining 18 patients have had arrhythmia 
recurrence at a mean of 5 rt 3 months after treatment. Ten 
patients (56%) have had no recurrent ventricular tachycar- 
diaifibrillation (mean follow-up 11 ? 5 months). Thus, 1 of 6 
patients with noninducible and 8 of 18 patients with inducible 
arrhythmia have had arrhythmia recurrences long-term (p < 
0.05). 
Adverse effects (Table 4). Thirty-four instances of side 
effects occurred in 28 patients (42%). Side effects severe 
enough to require withdrawal of sotalol occurred in 13 
patients (22%), 7 within I month and 6 later than 1 month 
(range 1 to 12). The drug dosage was decreased after 
discharge in an additional 10 patients (15%) because of side 
effects. The dosage of sotalol in patients with side effects 
was 305 ? 123 mgiday compared with 395 ? 149 mgiday for 
patients without side effects (p < 0.02). 
Cardiac complications developed in 16 putients. Five 
developed severe bradycardia, three of whom were treated 
with a permanent pacemaker. Nine patients experienced 
exacerbation of congestive heart failure during sotalol ther- 
apy (dose 338 -C 96 mglday). The mean ejection fraction of 
these patients was 0.30 2 0.08, and four had previously been 
in clinical heart failure. The ejection fraction of the group 
without drug-induced heart failure was 0.39 + 0.11 (p < 
0.03). Two patients developed symptomatic hypotension 
during sotalol loading. 
Arrhythmia exacerbation (Table 5). Six patients experi- 
enced arrhythmia exacerbation. The sotalol dose, QT inter- 
val and associated condition are listed in Table 5. The 
resultant arrhythmia was a monomorphic ventricular tachy- 
cardia in three patients and torsade de pointes in three 
patients. All arrhythmias resolved with a dose reduction or 
drug withdrawal. Temporary pacing was required to control 
the arrhythmia in two patients. For those patients with 
arrhythmia exacerbation associated with a change in dosage 
or the initiation of treatment, the arrhythmia developed 
within 48 h. One patient developed torsade de pointes with 
hypokalemia as a result of an adrenal adenoma. Serum 
potassium and magnesium levels were normal in the other 
patients. Four of the patients with arrhythmia exacerbation 
continue to do well taking sotalol at a lower dosage. 
Effects of sotalol in patients with an implanted defibrillator. 
Twenty-four patients with an implanted defibrillator were 
treated with sotalol. Two patients had the drug withdrawn 
Table 5. Arrhythmia Exacerbation in Six Patients 
(‘ase Dosage Clinical Sotalol-Induced QT Associated 
Yo. (mgiday) Arrhythmia Arrhythmia (s) Condition Outcome 
s 320 VT VT 0.5x Dosage increase Doing well on 
lower dose 
9 4x0 VT TdP 0.56 Dosage increase Doing well on 
lower dose 
I? 4x0 VT TdP 0.52 Dosage increase Doing well on 
lower dose 
I6 330 VF TdP - K’ 2.7 Doing well with 
adrenal 
adenoma 
removed 
19 X0 VT VT 0.56 First dose Resolved off 
sotalol 
22 320 VT VT 0.52 Dosage increase Resolved off 
sotalol 
TdP = torsade de pointes; other abbreviations as in Table 2. 
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Table 6. Effect of Sotalol on Spontaneously Occurring Arrhythmias in 25 Patients 
No. of Events/24 h Baseline Sotalol % Change p Value 
Single PVCs 2,570 * 2,908 1,606 + 2,676 37 NS 
Pairs 140 + 241 34 ? 67 76 NS 
Runs 9 t 27 I”2 88 co.05 
PVCs = premature ventricular complexes. 
during the loading phase because of drug inefficacy. Twen- 
ty-two patients were discharged on sotalol therapy. In four 
patients, sotalol was withdrawn because of side effects. Of 
the remaining 18 patients, 11 are doing well without inter- 
current defibrillator shocks (mean follow-up 12 ? 4 months), 
while one or more shocks have occurred in the other 7 
patients. All discharges were believed to be appropriate in 
that the patients had presyncopal symptoms before dis- 
charge. There was no known episode of ventricular tachy- 
cardia at a rate below the “rate cutoff’ of the device. All 
discharges were successful, and these seven patients remain 
on sotalol therapy (dose 363 + 124 mglday). 
Effects of sotalol on spontaneously occurring arrhythmias 
(Table 6). Twenty-five patients had a 24 h ambulatory ECG 
recording at baseline and at steady state sotalol therapy. 
Although sotalol decreased the frequency of premature 
ventricular complexes by 37%, pairs by 76% and runs of 
nonsustained ventricular tachycardia by 88%, this change 
was significant only for the number of episodes of non- 
sustained ventricular tachycardia. This action may reduce 
the number of defibrillator shocks for nonsustained ventric- 
ular tachycardia. There was no significant difference in the 
decrease in total premature ventricular complexes in those 
patients treated successfully over the long-term compared 
with those treated unsuccessfully. 
Discussion 
Clinical efficacy of sotalol. It is difficult to directly com- 
pare the efficacy of sotalol observed in this study with that of 
other antiarrhythmic agents. To do so would require a 
randomization of patients to treatment with various anti- 
arrhythmic drugs without regard to previous clinical drug 
trials or the results of electrophysiologic drug testing. A pure 
study of an antiarrhythmic drug alone in patients with 
life-threatening arrhythmias without the concomitant use of 
the implantable defibrillator in some of the higher risk 
patients may no longer be possible. Although all patients had 
a history of sustained ventricular tachycardia or ventricular 
fibrillation, or both, and 46% ot patients had at least one 
prior cardiac arrest, these patients may not be directly 
comparable with patients treated with other drugs for several 
reasons. Patients with the most severe left ventricular dys- 
function were excluded. Similarly, patients were previously 
refractory to numerous other drugs, and 23% had been 
unsuccessfully treated with amiodarone. Eleven patients 
whose ventricular arrhythmia was inducible while receiving 
oral sotalol were not discharged receiving the drug. These 
patients were not included in the analysis of sotalol effec- 
tiveness, and it is possible that continuing sotalol therapy in 
these patients would have lowered the actuarial incidence of 
sotalol efficacy. Patients previously treated with amiodarone 
were included, and the slowly diminishing drug levels may 
have falsely elevated sotalol efficacy. Despite these limita- 
tions, it appears that sotalol is frequently useful in patients 
with refractory, malignant ventricular arrhythmias. 
Antiarrhythmic agents that do not suppress all recur- 
rences of ventricular tachycardialjibrillation may still be of 
value (18). A drug may slow the rate of ventricular tachy- 
cardia such that it is less life-threatening or it may reduce the 
frequency of arrhythmia episodes requiring hospitalization 
or cardioversionldefibrillation by means of an implanted 
device. For this reason, we examined the efficacy of sotalol 
in controlling all recurrences of sustained ventricular tachy- 
cardia/fibrillation as well as its effects on reducing the 
prevalence of sustained arrhythmias. In our study, sotalol 
was effective in controlling all ventricular tachycardia/fibril- 
lation in only 22 patients (34%), but proved useful by 
reducing the frequency of arrhythmia recurrence in another 
11 patients (17%). Seven of these 11 patients had an im- 
planted defibrillator and clinical recurrent arrhythmias ter- 
minated by the device may have been fatal in its absence. 
The other four patients have required hospitalization for 
recurrent ventricular tachycardia, but the frequency of 
arrhythmia recurrence has markedly decreased on sotalol. 
Electrophysiologic testing. Oral sotalol prevented the in- 
duction of ventricular tachycardia/fibrillation in only 8 (20%) 
of 39 of our patients. Nademanee et al. (9) and Senges et al. 
(8) reported that intravenous sotalol prevented ventricular 
tachycardia/fibrillation inducibility in 15 of (45%) of 33 
patients and 12 (67%) of 18 patients, respectively, whereas 
Steinbeck et al. (lo), using oral sotalol, reported noninduci- 
bility in 44% of their patients. The lower efficacy reported in 
our study is likely explained by the use of a third extrasti- 
mulus. Preliminary data from a multicenter randomized 
study (1 l), using a third extrastimulus, indicate a 15% (8 of 
54 patients) efficacy of sotalol in preventing ventricular 
tachycardia/fibrillation induction. 
It is important to know the predictive value of electrophy- 
siologic testing for long-term eJicacy for any new anti- 
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arrhythmic ugent. It is well established (19-23) that drugs 
that suppress ventricular tachycardia/fibrillation induction 
tend to be effective in the long-term, whereas continued 
inducibility at the time of electrophysiologic drug testing is 
associated with a relatively high recurrence rate. Our data 
indicate that electrophysiologic studies are useful for pre- 
dicting the long-term efficacy of sotalol. With the use of an 
implanted defibrillator in patients for whom a ventricular 
tachycardia/fibrillation recurrence was thought to be life- 
threatening, we were able to continue 20 patients on sotalol 
therapy despite continued arrhythmia inducibility. Of these. 
44% experienced ventricular tachycardiaifibrillation recur- 
rence, a rate comparable with that of other antiarrhythmic 
agents, including amiodarone. Only 17% of the patients with 
noninducibility while taking sotalol experienced arrhythmia 
recurrence. 
Adverse effects. The incidence of side effects in our study 
is higher than that previously reported (I 1) for sotalol. Most 
of the side effects were associated with beta-adrenergic 
antagonism and frequently resolved with dose reduction. 
The effect of sotalol on left ventricular function remains 
unclear. Lengthening the action potential duration may 
increase contractility, and it has been suggested (24,251 that 
this effect of sotalol may offset the depressant action of 
beta-adrenergic receptor antagonism. Preliminary data in 
human subjects (26) indicate that the hemodynamic effects of 
sotalol are less than those of conventional beta blockers. 
Similarly, previous clinical studies (26,271 suggest that sota- 
lo1 infrequently aggravates heart failure. Our data are at 
variance with this. Although our patients with arrhythmia 
with the worst left ventricular function or only marginally 
compensated heart failure were excluded from this study. 
nine patients experienced worsened congestive heart failure. 
Had we not excluded patients at high risk for congestive 
heart failure, the incidence of heart failure would have 
undoubtedly been higher. These nine patients had signifi- 
cantly worse left ventricular function than the group as a 
whole, and we are now reluctant to use sotalol in patients 
with an ejection fraction ~0.30 or with a previous history of 
severe heart failure. This practice clearly precludes its use in 
a large number of patients with life-threatening ventricular 
arrhythmias. 
Arrhythmia exacerbation. Arrhythmia exacerbation with 
sotalol has been reported (28-31), particularly as torsade de 
pointes in association with overdosage, hypokalemia, exces- 
sive QT prolongation and bradycardia. Our data indicate that 
a proarrhythmic effect may be more frequent than previously 
thought. These patients’ QT intervals were prolonged, but 
the increase was in the upper range of the group as a whole. 
Similarly. they were receiving average doses of sotalol, all 
had normal renal function and all but one had normal serum 
potassium and magnesium. Also of interest was the fact that 
the arrhythmia was a monomorphic ventricular tachycardia 
in three patients and torsade de pointe in another three 
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patients. The arrhythmia worsening occurred within 48 h of 
the initial dosage or a dosage increase in all patients. It 
appears prudent, therefore, in addition to avoiding hypoka- 
lemia. that patients be monitored continuously during sotalol 
initiation or dosage increases. Prolongation of the QT inter- 
val >0.52 should probably be avoided. 
Implantable defibrillators. Despite the value of implanted 
defibrillators in preventing sudden death in patients with 
recurrent ventricular tachycardiaifibrillation. most patients 
require concurrent antiarrhythmic drug therapy to suppress 
frequent episodes of sustained or nonsustained ventricular 
tachycardia or prevent inappropriate defibrillator shocks 
triggered by sinus tachycardia or atrial tachyarrhythmias 
with rapid atrioventricular conduction (32). An ideal anti- 
arrhythmic agent to be used with an implanted defibrillator. 
in addition to being efficacious for ventricular arrhythmias. 
should prevent atria1 arrhythmias, block excessive sinus 
tachycardia and slow atrioventricular conduction during 
supraventricular arrhythmias. The drug should also slow the 
ventricular tachycardia cycle length enough to prevent syn- 
cope before its automatic termination. but not slow it below 
the rate cutoff of the device. Finally. the drug should either 
have no effect on or lower defibrillation threshold. In many 
ways. sotalol fits this description because of its atrial as well 
as ventricular antiarrhythmic actions and its beta-adrenergic 
blocking effects. During sotalol therapy, none of our patients 
with an implanted defibrillator received inappropriate dis- 
charges nor was any discharge unsuccessful for terminating 
their arrhythmias. A formal test of defibrillation threshold 
before and after sotalol would have been desirable, but was 
not feasible in the present study. 
Conclusions. The results of this study suggest that sotalol 
is frequently useful in the control of intractable, life- 
threatening ventricular arrhythmias. Although the incidence 
of limiting side effects is high and there is a substantial risk 
of arrhythmia exacerbation, sotalol was a valuable adjunct to 
available drugs. In addition to its antiarrhythmic activity. 
sotalol also produces several additional cardiac effects that 
are particularly advantageous when used concurrently with 
an implanted defibrillator. 
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